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Background: The management of patients with angiographically intermediate coronary lesions is a major clinical
issue. Fractional flow reserve provides validated functional insights while optical coherence tomography provides
high resolution anatomic imaging. Both techniques may be applied to guide management in case of
angiographically intermediate coronary lesions. Moreover, these techniques may be used to optimize the result of
percutaneous coronary intervention. We aim to compare the clinical and economic impact of fractional flow reserve
versus optical coherence tomography guidance in patients with angiographically intermediate coronary lesions.
Methods/Design: Patients with at least one angiographically intermediate coronary lesion will be randomized
(ratio 1:1) to fractional flow reserve or optical coherence tomography guidance. In the fractional flow reserve arm,
percutaneous coronary intervention will be performed if fractional flow reserve value is ≤0.80, and will be
conducted with the aim of achieving a post-percutaneous coronary intervention fractional flow reserve target value
of ≥0.90. In the optical coherence tomography arm, percutaneous coronary intervention will be performed if
percentage of area stenosis (AS%) is ≥75% or 50 to 75% with minimal lumen area <2.5 mm2, or if a major plaque
ulceration is detected. In case of percutaneous coronary intervention, optical coherence tomography will guide the
procedure in order to minimize under-expansion, malapposition, and edge dissections.
Cost load and clinical outcome will be prospectively assessed at one and thirteen months. The assessed clinical
outcome measures will be: major cardiovascular events and occurrence of significant angina defined as a Seattle
Angina Questionnaire score <90 in the angina frequency scale.
Discussion: The FORZA trial will provide useful guidance for the management of patients with coronary artery
disease by prospectively assessing the use of two techniques representing the gold standard for functional and
anatomical definition of coronary plaques.
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The decision on when and how to treat patients with
coronary artery disease represents a major clinical issue
and is usually based on a clinical evaluation combined
with analysis of coronary angiography. Yet a growing
body of evidence suggests that coronary angiography
fails to allow detailed assessment of coronary athero-
sclerotic plaque morphology and severity [1]. As a con-
sequence, in recent years a series of novel technologies
have been developed in order to improve the assessment
of patients with coronary artery disease [2-4]. Their use
may improve the decision making process in patients
with equivocal findings at coronary angiography, such as
patients with angiographically intermediate coronary le-
sions (AICL) [1].
The first of these strategies is represented by fractional
flow reserve (FFR), defined as the ratio of pressure distal
to the stenosis and aortic pressure after induced max-
imal hyperemia. Its normal value is 1, while a value of
0.75 has been initially purposed as the cutoff in identify-
ing the presence of myocardial ischemia in a validation
study of comparison with non-invasive tests, showing a
93% diagnostic accuracy with 100% specificity and an
88% sensitivity [5]. The same cutoff has been confirmed
in the DEFER study, in which deferred revascularization
of intermediate stenosis was shown to be safe if FFR was
above 0.75, with similar long term outcomes in patients
in both the percutaneous coronary intervention (PCI)
group and those in the defer PCI group [6].
The more conservative cutoff of 0.80 has been tested
in two large randomized clinical trials, showing in the
drug-eluting stent era, a net clinical and economic ad-
vantage from a FFR-guided revascularization strategy
[7,8]. On the basis of the FAME [7] and FAME 2 [8] tri-
als, a cutoff value of 0.80 is currently being used in clin-
ical practice in order to identify the ischemic burden
associated with AICL, and to guide the choice betweenTable 1 Main studies about impact of adjunctive intracoronar
lesions
Study Year Patients Technique Lesions Compar
































FFR, fractional flow reserve; FUP, follow up; IVUS, intravascular ultrasound; LAD, left
MI, myocardial infarction; OMT, optimal medical therapy; PCI, percutaneous coronarrevascularization and optimal medical therapy. As
shown in Table 1, FFR remains the main technique to be
used in clinical studies exploring the impact of adjunct-
ive invasive assessment strategy in guiding the manage-
ment of patients with AICL.
On the other hand, frequency domain technique op-
tical coherence tomography (FD-OCT), an intracoronary
imaging technology warranting quick and precise evalu-
ation of coronary lumen and the vessel wall [4], has en-
tered into clinical practice, providing promising clinical
results when applied to guide PCI [9]. On such a basis,
most of interventional cardiology centers are (or are go-
ing to be) equipped with one or both of the equipment
for FFR and FD-OCT. Due to the absence of dedicated
trials (Table 1) [6,10-14], the decision of when to use
one of these two tools is left to the operator and/or
centre preference. Yet, these two techniques have a com-
pletely different approach to plaque evaluation, since
stenosis-related flow limitation and plaque morphology
may influence different aspects of the natural history of
ischemic heart disease. Thus, we designed the present
prospective clinical trial aimed at comparing the clinical
and economic implications associated with the selection




The FORZA study is an open label prospective single
centre randomized trial comparing the costs and the rate
of adverse clinical outcomes in patients randomized to
FFR versus FD-OCT guided PCI on AICL.
Consecutive patients with evidence of AICL, defined
as a coronary lesion with a visually estimated percentage
diameter stenosis ranging from between 30 and 80%
[15], will be prospectively enrolled and randomized to
FFR guidance or FD-OCT guidance at a ratio of 1:1.y techniques to guide PCI in intermediate coronary
ison FUP MACE Recurrent Angina
d PCI
d OMT
5 years ↔ in PCI vs OMT
(3.3% vs 7.9%, P = n.s)
↓ in OMT vs PCI
(43.0% vs 33.0%, P = 0.02)
d PCI
d OMT
13 months ↓ in PCI vs OMT
(5% vs 23%, P = 0.005)
↓ in PCI vs OMT
(9.0% vs 41.0%, P = 0.002)
d PCI
d OMT
14 months ↔ in PCI vs OMT
(7.0% vs 16.0%, P = n.s.)
↓ in PCI vs OMT
(20.0% vs 36.0%, P = 0.008)
d PCI
ed PCI
1 year ↔ in FFR vs IVUS




40 months ↓ in OMT vs PCI




53 months ↔ in PCI vs OMT
(13.3% vs 6.9%, P = n.s)
________
anterior descending; LM, left main; MACE, major cardiovascular event;
y intervention.
Burzotta et al. Trials 2014, 15:140 Page 3 of 9
http://www.trialsjournal.com/content/15/1/140Each patient will complete a Seattle Angina Question-
naire (SAQ) before intervention, at one month, and thir-
teen months follow up. Details on SAQ are reported in
the Methods/Design section. FFR and FD-OCT assess-
ment will be performed at the site of AICL according to
technical details reported in the Methods/Design section
below. The study flow chart is summarized in Figure 1.
The specific inclusion and exclusion criteria for the
study are reported in Table 2.
Study endpoints
The occurrence of significant residual angina (<90 score
at SAQ angina frequency scale) at 13 months represents
the primary endpoint of the study.
Major cardiovascular events (MACE), defined as the
occurrence of death, myocardial infarction (MI) and tar-
get vessel revascularization (TVR), will be prospectively
assessed. Since the rate of MACE is anticipated to be
low, and most of the procedures in patients with AICL
are performed with the aim of improving symptoms, the
recurrence of significant angina (defined as an SAQ
score <90 on the angina frequency scale) will be pro-
spectively assessed as well.
The first secondary endpoint will be the combined
endpoint of recurrence of significant angina or MACE at
13 months follow up. However, in the case of a MACE
rate absolute difference of >1% between the two study
arms, this combined endpoint will be considered as the
primary endpoint of the study.Figure 1 Study flow chart. (AS%, percentage of area stenosis; FFR, flow fr
tomography; PCI, percutaneous coronary intervention; SAQ, Seattle anginaA further secondary endpoint will be the global costs
of the strategy (FFR or FD-OCT guided) at one and thir-
teen months follow up.
Procedure description
A guiding catheter (shape and size chosen by the oper-
ator) will be placed at the coronary ostium. Then, ac-
cording to randomization, FFR or FD-OCT assessment
will be performed as described below. PCI will be per-
formed at the same time or in a second procedure
(‘staged procedure’) according to the decision of the op-
erator only if the pre-specified FFR or FD-OCT criteria
are fulfilled, otherwise the patient will be discharged on
optimal medical treatment as recommended by inter-
national guidelines [16]. The decision regarding pre- and
post-dilation, and the type and number of stents needed
to cover all of the diseased segment will be left to opera-
tor’s discretion. Thereafter, FFR or FD-OCT will be per-
formed and further optimization of PCI procedure will
be performed as described below.
FFR guidance
After intravenous administration of heparin 100 IU/kg, a
0.014 inch pressure monitoring guidewire (Pressure
Wire Certus, St. Jude Medical, St. Paul, New Mexico,
United States) will be calibrated and advanced into the
guiding catheter until the pressure transducer will be
just outside its tip, allowing equalization of the pressure
measured by the sensor on the guidewire with thatactional reserve; MLA, minimal lumen area; OCT, optical coherence
questionnaire).
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Clinical Clinical
Age >18 years Age <18 years
Diagnosis of ischemic heart disease Inability to give informed consent
Female with child-bearing potential
Angiographic Life expectancy <12 months
Single vessel disease with angiographically intermediate coronary lesion OR Factors making clinical follow up difficult (such as no fixed address)
Multivessel disease with only angiographically intermediate coronary lesion OR Poor cardiac function as defined by left
ventricular global ejection fraction ≤30%
Multivessel disease with at least one angiographically intermediate
coronary lesion and already treated angiographically critical stenosis
Recent (<7 days) ST-segment elevation Myocardial infarction
Recent (<48 hours) Non ST-segment elevation myocardial infarction
Prior ST-segment elevation myocardial Infarction in the territory
supplied by the vessel with the intermediate under investigation
Severe myocardial hypertrophy (interventricular septum
thickness >15 mm, ECG Sokolow’s criteria fulfilled)
Severe valvular heart disease
Significant platelet count alteration
(<100,000 cells/mm3 or >700,000 cells/mm3)
Gastrointestinal bleeding requiring surgery or
blood transfusions within the four weeks previous
History of clotting pathology
Known hypersensitivity to aspirin, heparin, or contrast dye
Advanced renal failure with a glomerular filtration rate <30 ml/min
Angiographic
Multivessel disease with one or more untreated
angiographically critical stenosis or coronary occlusion.
Lesions in coronary artery bypass grafts
Multivessel disease requiring coronary aortic bypass graft intervention
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then be advanced beyond the AICL under examination.
Special attention will be paid to avoid arterial pressure
wave damping, non-selective cannulation of coronary
ostia, and variations in the position of the pressure wire
tip. FFR will be calculated as the lowest ratio of distal
coronary pressure (Pd) divided by aortic pressure (Pa)
after achievement of maximal hyperemia, obtained using
intravenous or intracoronary adenosine according to our
hospital’s internal protocol [17]. The femoral or brachial
vein will be used for intravenous administration of
140 μg Kg-1 min-1 adenosine and maximal hyperemia
will be assumed at least after 60 seconds in the presence
of stable systemic blood pressure decrease compared to
baseline remaining for at least 10 heart-beats. In case of
intracoronary infusion, incremental boli of intracoronary
adenosine (60, 300 and 600 μg) will be administered
with each next dose given at least 60 seconds apart, or
after returning to baseline hemodynamic conditions.
Each administration will be performed within 5 to
10 seconds and rapidly flushed by saline solution. Thefollowing higher dose will not be administered in the
case of an atrio-ventricular block lasting more than 5 sec-
onds. In such cases, intravenous adenosine will be used
to induce maximal hyperemia [17]. Similarly, in the case
of FFR values between 0.81 and 0.83 with 600 μg intra-
coroary adenosine, FFR will be retested using intraven-
ous adenosine [17]. Finally, an FFR value of ≤0.80 will be
considered abnormal. When more than one stenosis is
present in the same artery, a pull-back maneuver under
maximal hyperemia to determine the exact location and
physiological significance of sequential stenosis will be
adopted.
If an FFR value of >0.80 is measured on the target
AICL, patients will be treated with optimal medical ther-
apy only. If an FFR of ≤0.80 is obtained, patients will
undergo a FFR-guided PCI. This means that the patient
will undergo conventional PCI with stenting of the AICL
in order to achieve a post-stenting FFR ≥0.90. If post-
stenting FFR is <0.90 a further post-dilation of the stent
will be performed, and if FFR remains at <0.90, a pull-
back of the wire to identify another possible pressure
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5 mm from the stent will be performed according to
physician’s preference.
FD-OCT guidance
FD-OCT images will be acquired at the site of AICL with
a commercially available system (C7 System; LightLab
Imaging Inc/St Jude Medical, Westford, Massachusetts,
United States) after the FD-OCT catheter (C7 Dragonfly;
LightLab Imaging Inc/St Jude Medical, Westford, Massa-
chusetts, United States) is advanced to the distal end of
the target lesion. The entire length of the region of interest
will be scanned using the integrated automated pull-back
device at 20 mm/s. During image acquisition, coronary
blood flow will be replaced by the continuous flushing of
contrast media directly from the guiding catheter at a rate
of 4 ml/s with a power injector in order to create a virtu-
ally blood-free environment. All images will be recorded
digitally, stored, reviewed and analyzed with proprietary
software (LightLab Imaging) after confirming proper cali-
bration settings of the Z-offset. Immediately after confirm-
ation of successful FD-OCT image acquisition, the
following measures will be performed: minimal lumen
area (MLA) (defined as cross section area at the smallest
lumen area level), proximal reference lumen area (pRLA)
(defined as cross section at the frame with largest lumen
within 10 mm proximal to MLA and before any major
side-branch), distal reference lumen area (dRLA) (defined
as cross section at the frame with largest lumen within
10 mm distal to MLA and before any major side-branch)
and mean reference lumen area (mRLA) (defined as
(pRLA + dRLA)/2).
On the basis of these parameters, AS% will be calculated
using the following formula: (mRLA-MLA)/mRLA × 100.
PCI will be performed when one of the following con-
ditions will be present: AS% ≥ 75%, AS% from 50% to
75% with MLA <2.5 mm2, and/or major plaque ulcer-
ation evidence at FD-OCT. Major plaque ulceration will
be defined as a recess in the plaque beginning at the
luminal-intimal border [4]. The described criteria have
not been used in the past and have been developed for
the present study. At the time the protocol was con-
ceived, only three small studies have directly compared
FD-OCT with FFR in order to find a cutoff for one of
the anatomic parameters provided by FD-OCT in order
to predict FFR [18-20]. Nevertheless a definite cutoff has
not been identified and a broadly poor accuracy of FD-
OCT in detecting a FFR of ≤0.80 has been described.
For this reason the definition of FD-OCT criteria for
this study was based on the concept that no unique cut-
off value of any parameter is currently known. In par-
ticular, the percentage and small residual cross-section
area are known to correlate independently with the
functional significance of coronary stenosis [21]. Overall,the accuracy of MLA seems to compare favorably with
that of AS%, but MLA cutoffs are known to differ across
different coronary vessels and study populations [22].
Moreover, when the AS% is above 75 to 80%, false
positives are virtually absent [18], meaning that at these
levels AS% is probably a reliable cutoff for intervention
(first criterion). When such an extreme situation is not
present, we decided to improve the accuracy by combin-
ing small MLA with appreciable AS% (second criterion)
in order to limit false positives (and indirectly adjusting
for vessel size). In dealing with a gray zone for the AS%
parameter, a looser MLA cutoff of 2.5 mm2 has been
chosen in this case in order to reduce the possibilities of
false negative.
Finally, since some adverse events may occur in pa-
tients with FFR-negative lesions (0.2% occurrence of MI
and revascularization rate of 3.2% in FFR >0.80 group of
the FAME study, and 3.3% occurrence of combined pri-
mary endpoint in the defer group of the DEFER study)
[6,7] and untreated lesions with complex morphology
may be responsible, we hypothesize that stenosis with
the typical features of complicated atherosclerosis (as
detectable by FD-OCT) may particularly benefit from
treatment (third criterion). In this case only major
plaque ulceration was considered as a criterion as it is
the hallmark of existing plaque instability. The presence
of a thin fibrous cap atheroma (TCFA) was not identified
as a criterion for PCI or AICL. Indeed, even if TCFA are
associated to possible future plaque instability and may
have a prognostic relevance [23], no randomized studies
have so far shown a clinical benefit in a preventive stent-
ing strategy for this kind of lesion.
In FD-OCT patients undergoing PCI, FD-OCT will
also be used to check PCI results and to guide further
optimization of the PCI results, if required. In particular,
after the procedure a FD-OCT run will be performed
and further intervention (balloon dilation and/or stent
implantation) will be performed in the presence of:
major stent strut malapposition (defined as a distance
between the strut and vessel wall of greater than 350 μm or
<350 but >200 μm for a length >600 μm (appreciable in >3
contiguous frames at a pull-back speed of 20 mm/sec)
[9,24]), major stent under-expansion (defined as: in-
stent minimal cross-section area of <75% of the RLA
[9,25]) and major edge dissection (defined as dissecti-
on >600 μm (appreciable in >3 contiguous frames at a
pull-back speed of 20 mm/sec) [24,26]).
The feasibility of FD-OCT guidance for PCI has been
recently reported by several authors [9,27] and it has
been shown that it may improve prognosis when com-
pared to the ‘classical’ angiographic guidance [28]. The
concept of FD-OCT guidance for PCI is based on the
possibility that stent-related complications may influence
the long term the occurrence of stent failures [29]. Yet,
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plaque prolapse, stent under-expansion, and malapposi-
tion are frequently detectable by FD-OCT and may evolve
positively in the majority of cases managed conservatively
[30]. In a retrospective analysis of our FD-OCT proce-
dures, the above mentioned quantitative cutoffs for treat-
ment of FD-OCT detectable complications were found in
one third of cases (unpublished data). Thus, we planned
to try to correct by further treatment, only such ‘major’
stent complications among the minor ones detected by
FD-OCT.Post-procedural management
All patients will undergo cardiac damage markers (Crea-
tin-kinase-MB and Troponin I) assessment before the
procedure (when feasible), at 6 and 24 hours after PCI.
Thereafter, further blood samples will be performed only
if clinically indicated. After PCI, patients will be given
aspirin (75 to 100 mg/die) on an ongoing basis and clo-
pidogrel (75 mg/die) according to the European Society
of Cardiology Guidelines [16].Data set and clinical outcome measures
Clinical data (risk factors, medical history) of enrolled
patients will be collected in a dedicated electronic data-
base at the time of the intervention procedure. The date
of discharge will be systematically recorded. After dis-
charge, patients will be contacted by phone or ambula-
tory visit at 1, 6, and 13 months. A follow up coronary
angiography will be performed only in the case of typical
symptoms or signs of ischemia on noninvasive testing,
whereas repeat revascularization will be undertaken in
the case of significant (>50%) angiographic stenosis.
In the case of suspected adverse clinical events, pertin-
ent medical records will be carefully reviewed to ascer-
tain the occurrence of MACE. Deaths of an unknown
cause will be considered of cardiovascular origin. MI will
be defined according to the third universal definition of
myocardial infarction by a combination of chest discom-
fort, typical ECG modifications and the dynamic increas-
ing of troponin T (>99th percentile upper reference
limit) related to atherosclerotic plaque rupture, ulcer-
ation, fissuring, erosion, or dissection with resulting
intraluminal thrombus in one or more of the coronary
arteries (Type 1 MI) [31]. Post-procedural MI will be de-
fined as a rise of creatinin-kinase MB more than five
times the 99th percentile upper reference limit during
the 48 hours after PCI [32]. Thereafter, peri-procedural
MI (Type 4a MI) will be defined by a combination of
symptoms, typical ECG modifications and elevation of
troponin values of more than five times the 99th per-
centile upper reference limit in patients with a normal
baseline, or a rise of troponin values of greater than 20%if the baseline values are elevated, and are stable or fall-
ing [31].
TVR will be defined as repeated clinically-driven re-
vascularization by either PCI or coronary-aortic bypass
grafting involving the treated vessel. Stent thrombosis
will be classified by the Academic Research Consortium
definition as definite, probable, or possible and as early
(0 to 30 days), late (31 to 360 days), or very late (over
360 days) [33].
Detailed clinical assessment of angina status will take
place at one and thirteen months by asking the patients
to fulfil the SAQ, a disease-specific functional status
measure to quantify the physical and emotional effects
of coronary artery disease [34]. It consists of a question-
naire of eleven questions grouped into five main scales
measuring clinically important dimensions of coronary
artery disease: physical limitation, angina stability, angina
frequency, treatment satisfaction, and disease perception.
SAQ is scored by assigning each response an ordinal
value, beginning with 1 for the response that implies the
lowest level of functioning, and summing items within
each of the five scales. Scale scores are then transformed
to a 0 to 100 range. Because each scale monitors a unique
dimension of coronary artery disease, no summary is gen-
erated. Yet, due to the evidence of overlaps between the
five assessment scales, a <90 score on the angina fre-
quency scale will be used to define ‘significant residual an-
gina’ (see primary study endpoints session) [34].
Costs analysis
The costs of the procedures will be calculated by deter-
mining the amount of guiding catheters, regular wires,
pressure wires, FD-OCT-catheters, balloon dilatation
catheters, stents, antiplatelet therapy, adenosine, contrast
media, and hospital days used for each patient’s proced-
ure. These will be multiplied by the cost of each re-
source in Euros. Personnel and laboratory time costs
will not be included because assumed to be similar be-
tween the two strategies.
Costs of repeated PCI without myocardial infarction,
repeated PCI in the setting of a non peri-procedural
myocardial infarction and coronary artery bypass graft-
ing will be based on the Italian National Health System’s
reimbursement rate per diagnosis-related group.
Regulatory issues
The study protocol was conceived in September 2012,
approved by the Ethical Committee of the Catholic Uni-
versity of the Sacred Heart, Polcilinico A. Gemelli Rome,
and registered to clinicaltrial.gov (Reference number
NCT01824030). The study will be performed in accord-
ance with the ethical standards of the responsible commit-
tees on human experimentation and with the Helsinki
Declaration. Each patient willing to participate to the
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aims of the study, features and risks related to the
procedure.
Sample size calculation for clinical outcome
FFR-based treatment has proven to be superior to stand-
ard (based on angiography only) treatment by reducing
the occurrence of MACE in the long-term [35]. Yet an-
gina relief (an important determinant of quality of life in
patients with ischemic heart disease) was not amelio-
rated by FFR guidance in a recent trial [7]. Thus, the
FORZA trial aims to test if FD-OCT guidance may help
to improve the clinical management of patients with is-
chemic heart disease and inconclusive results at coronary
angiography. Since hard clinical endpoints are expected to
have low frequency and PCI (especially in patients with
good prognosis) is performed with the aim of improving
the quality of life by eliminating angina and improving
heart function, the occurrence of significant residual
angina (<90 score at SAQ angina frequency scale) at
13 months has been considered as the primary endpoint.
For sample size calculations, we focused our attention
on the clinical outcome at 13 months (a timepoint
chosen assuming that most of patients had completed
their 12-month double antiplatelet therapy one month
before). Then, based on the FAME trial [7], we anticipate
20% of patients will be suffering from persistent angina
at follow up in the FFR guidance group. Thus, 20% of
patients are expected to have reached the primary end-
point at 13 months in the FFR guidance group. For the
present study, we hypothesize that FD-OCT guidance
could be able (due to the treatment of a greater number
of stenoses and the optimization of stenting procedures
which may reduce the rate of untreated angina-causing
lesions) to reduce the occurrence of the primary end-
point by 50%. As a consequence, a total number of 400
patients (200 randomized to FFR guidance and 200 to
FD-OCT guidance) has been calculated to be needed
with an alpha error of 5% and a beta error of 20%.
This sample size is also suitable to satisfy the second-
ary endpoint of the study, represented by a combination
of MACE and/or relief from angina at 13-month follow
up. Indeed we assume to have a 5% rate of MACE in the
FFR guidance group, in line with the rate observed in a
previous study of patients with intermediate lesions
treated on the basis of FFR [10]. Thus, combined with
the 20% of patients suffering persistent angina at follow
up in the FFR guidance group, 25% of patients are ex-
pected to have reached the secondary endpoint at
13 months in the FFR guidance group. Since we expect
a significant reduction in angina but not in MACE oc-
currence in the FD-OCT patients, we assume a 50% re-
duction (exclusively due to angina relief ) of the
secondary endpoint in this group. As a consequence, atotal number of 304 (152 randomized to FFR guidance
and 152 to FD-OCT guidance) has been calculated to
satisfy the secondary endpoint requirements, with an
alpha error of 5% and a beta error of 20%.
Finally, since the sample size is strongly dependent on
the rate of events observed in the reference group (and
figures in the literature are highly variable), when the
first 150 patients complete the 13-month follow up, an
interim analysis will be performed and eventually an
amendment with a novel sample sizing will be calculated
in the case of >30% difference between expected and ob-
served rates.
Sample size calculation for peri-procedural management
costs
The costs for each arm are anticipated to be the com-
bination of diagnostic procedural costs, interventional
procedures (eventually derived from the diagnostic ones)
and costs related to events occurring during the follow
up. On the basis of the NASCI study, we expect a 30%
of PCI in the FFR-guided arm [17]. Contrastingly, ac-
cording to our experience (three years FD-OCT experi-
ence at our institution, unpublished data), PCI is
anticipated to be performed in about 50% of the FD-
OCT-guided arm. Thus considering the mean costs of a
FFR-guided PCI (3600€ for PCI + 940€ for the pressure
wire + 170€ for adenosine = 4710€) and of an FD-OCT
guided PCI (3600€ for PCI + 1600€ for the FD-OCT
catheter = 5200€) and the costs of a coronary angiog-
raphy with FFR (500€ for coronary angiography + 940€
for the pressure wire plus 170€ for adenosine = 1610€)
and of a coronary angiography with FD-OCT (500€ for
coronary angiography + 1600€ for FD-OCT catheter =
2100€) we expect an overall costs reduction of 30% in
the FFR-guidance group compared to the FD-OCT guid-
ance group. Assuming no occurrence, or at least a simi-
lar occurrence of MACE, or recurrence of angina at
30 days follow up in both arms, we expect an overall
30% reduction of costs at 30 days follow up in the FFR-
guided arm. A total number of 220 patients (110 ran-
domized to FFR guidance and 110 to FD-OCT guidance)
with an alpha error of 5% and a beta error of 20% has
been calculated to be needed to test this hypothesis.
Study limitations
The major anticipated limitation of the present study is
that it is an open-label and not a double-blinded trial.
The treating physicians cannot be blinded since a FFR-
guided procedure is fairly different from an FD-OCT-
guided PCI.
Trial status
The trial is in the patient recruitment phase, started on
April 2013.
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